Floatz logo

Capecitabine

Brain Tumor, Primary

Northwell HealthSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Brain Tumor, Primary cohort.

Asset / SponsorPhaseRating
4-demethyl-4-cholestryloxycarbonylpenclomedine
DEKK-TEC, Inc.
Phase 2B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Entrectinib
Hoffmann-La Roche
Phase 2CCC
5-ala
Constantinos Hadjipanayis
Phase 2CCC
Irinotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC

View all 28 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →